RHHBY - This Drug By Roche And Novartis Reduces Allergic Reactions Across Multiple Foods For People With Food Allergies | Benzinga
Monday, Roche Holdings AG (OTC:RHHBY) announced data from Stage 1 of the National Institutes of Health (NIH)-sponsored pivotal Phase 3 OUtMATCH study of Xolair (omalizumab) in patients allergic to peanuts and at least two other common foods were published in the New England Journal of Medicine.
The data was featured in a late-breaking symposium at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting.
Roche and Novartis AG (NYSE:NVS) are co-developing and co-promoting Xolair.
The study showed that treatment with Xolair increased the amount of peanuts, milk, egg, wheat, and tree nuts (cashew, hazelnut, and walnut) that it took to cause moderate to severe allergic reactions in multi-food allergic people as young as one ...